Pancreatic Cancer Research

ResearcherOkayama UniversityActive in the last 2 years

Koichiro Tsutsumi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0001-5728-6538; OpenAlex author ID A5008381633. Sources: OpenAlex.

Their work

Papers
13
Trials
0
Grants
0
Labs led
0
Collaborators
24
Papers, trials and grants by year

2011: 1 paper · 2012: 1 paper · 2013: 1 paper · 2014: none · 2015: 3 papers · 2016: none · 2017: 1 paper · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 2 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 13

  1. Clinical Significance of a Cell-Of-Origin-Based Classification in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1111/cas.70533↗
  2. A case of pancreatic ductal adenocarcinoma growing within the pancreatic duct mimicking an intraductal tubulopapillary neoplasm. Co-author DOI 10.1007/s12328-025-02098-y↗
  3. Current status of endoscopic ultrasound-guided antitumor treatment for pancreatic cancer. Co-author DOI 10.1111/den.14815↗
  4. Cysts or necrotic components in pancreatic ductal adenocarcinoma is associated with the risk of EUS-FNA/B complications including needle tract seeding. Co-author DOI 10.1016/j.pan.2023.10.018↗
  5. Association between BRCA Gene Variants and the Response to Modified FOLFIRINOX in Patients with Unresectable Pancreatic Cancer. Co-author DOI 10.18926/amo/65974↗
  6. Efficacy and safety of chemotherapy after endoscopic double stenting for malignant duodenal and biliary obstructions in patients with advanced pancreatic cance… Co-author DOI 10.1186/s12876-018-0886-8↗
  7. Utility of serum DNA as a marker for KRAS mutations in pancreatic cancer tissue. Co-author DOI 10.1016/j.pan.2016.12.011↗
  8. Detection of K-ras gene mutation by liquid biopsy in patients with pancreatic cancer. Co-author DOI 10.1002/cncr.29364↗
  9. Prognostic value of altered N-glycosylation of circulating glycoproteins in patients with unresectable pancreatic cancer treated with gemcitabine. Co-author DOI 10.1097/mpa.0000000000000321↗
  10. Serum anti-60S ribosomal protein L29 antibody as a novel prognostic marker for unresectable pancreatic cancer. Co-author DOI 10.1159/000371545↗
  11. Clinical utility of high-throughput glycome analysis in patients with pancreatic cancer. Co-author DOI 10.1007/s00535-012-0732-7↗
  12. Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy. Co-author DOI 10.1016/j.pan.2012.07.009↗
  13. A 4-week versus a 3-week schedule of gemcitabine monotherapy for advanced pancreatic cancer: a randomized phase II study to evaluate toxicity and dose intensit… Co-author DOI 10.1007/s10147-011-0237-z↗

Closest collaborators

The 24 strongest of 24 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Kazuyuki Matsumoto · 6 shared papers, 2017–2025 · strength 1.07
  2. Hironari Kato · 11 shared papers, 2011–2025 · strength 1.05
  3. Motoyuki Otsuka · 4 shared papers, 2023–2026 · strength 0.97
  4. Shigeru Horiguchi · 6 shared papers, 2017–2026 · strength 0.93
  5. Yuki Fujii · 4 shared papers, 2023–2026 · strength 0.79
  6. Hiroyuki Terasawa · 3 shared papers, 2023–2026 · strength 0.55
  7. Daisuke Uchida · 4 shared papers, 2017–2026 · strength 0.50
  8. Kosei Takagi · 2 shared papers, 2025–2026 · strength 0.47
  9. Hideaki Kinugasa · 4 shared papers, 2015–2026 · strength 0.37
  10. Tatsuya Kikuchi · 2 shared papers, 2023–2026 · strength 0.36
  11. Soichiro Ako · 2 shared papers, 2017–2026 · strength 0.28
  12. Ryosuke Sato · 1 shared paper, 2025 · strength 0.25
  13. Kazuhide Yamamoto · 6 shared papers, 2011–2015 · strength 0.23
  14. Kazuya Yasui · 1 shared paper, 2026 · strength 0.22
  15. Shinichiro Muro · 3 shared papers, 2015–2018 · strength 0.20
  16. Kazuhiro Nouso · 5 shared papers, 2012–2017 · strength 0.20
  17. Koji Miyahara · 3 shared papers, 2013–2015 · strength 0.11
  18. Hiroyuki Okada · 1 shared paper, 2018 · strength 0.08
  19. Hiroyuki Okada · 2 shared papers, 2012–2015 · strength 0.07
  20. Shin‐Ichiro Nishimura · 2 shared papers, 2013–2015 · strength 0.07
  21. Hiroyuki M. OKADA · 1 shared paper, 2017 · strength 0.06
  22. Ken Hirao · 2 shared papers, 2011–2012 · strength 0.05
  23. Hirofumi Kawamoto · 2 shared papers, 2011–2012 · strength 0.05
  24. Ryo Harada · 1 shared paper, 2011 · strength 0.02

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.